No products in the cart.
Biocare introduces the Lung Adeno-2™ and Lung Squamous-2™ Multiplex IHC tests which aid in the critical differentiation of NSCLC squamous cell carcinoma vs. adenocarcinoma(1) with 100% specificity for squamous cell carcinoma and 79% sensitivity for adenocarcinoma. This differentiation is a critical component in therapeutic decisions such as the use of VEGF or EGFR inhibitors. Using Biocare’s simultaneous Multiplex IHC technology, the Lung Adeno-2™ (TTF-1 + Napsin A) and Lung Squamous-2™ (p63 + CK5) tests allow for the immunohistochemical (IHC) analysis of poorly differentiated lung adenocarcinomas vs. squamous cell carcinomas on a single patient slide.
(1)Tacha et al., Distinguishing Adenocarcinoma from Squamous Cell Carcinoma in the Lung Using Double Stains, Mod Pathol 2010; 23 Suppl 1:415A- 416A.
About Biocare Medical
Biocare Medical, LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC tests which provide increased confidence at critical diagnostic decision points, impacting patient therapy while accelerating turnaround time. Biocare’s advanced micro-polymer™ detection enables unsurpassed specificity and sensitivity. PROMARK™ and “mouse on mouse” IHC detection kits are optimized for rat and mouse tissues and feature proprietary blocking and retrieval reagents, resulting in virtually background free IHC staining.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets with novel tissue immunohistochemistry and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.